ClinicalTrials.gg
CompletedNCT01222884Updated Dec 2, 2015Results posted

A Randomized, Comparative, Open-label Study of IV Monofer® Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With IV Iron Sucrose in Subjects With CKD-5D

A Phase 3 interventional study of Monofer and Iron sucrose in Chronic Kidney Disease Stage 5 (Dialysis Dependent), sponsored by Pharmacosmos A/S. Completed at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-02.

Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
351
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Renal Insufficiency, Chronic with a site in India — 18 open to participants now, 25 under way, 15 of them phase 3. Renal Insufficiency, Chronic · India.

Enrollment
36th of 54
351 · median 570
Started
2011
with 1 other
Phase 3
32 of 64
9 open now
Registered
6th of 64
by date

Among the 64 studies in Renal Insufficiency, Chronic with a site in India, this one is the 36th largest by enrollment of the 54 interventional ones that give a count, is one of 2 that started in 2011, is one of 32 in phase 3, and was the 6th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

18 of the 64 studies in Renal Insufficiency, Chronic with a site in India are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Renal Insufficiency, Chronic with a site in India, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of intravenous iron isomaltoside 1000 with intravenous iron sucrose in patients suffering from Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D).

03

Conditions studied

  • Chronic Kidney Disease Stage 5 (Dialysis Dependent)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects with a diagnosis of CKD-5D, in dialysis therapy for at least 90 days prior to inclusion, will be included if they meet all of the following criteria:

  1. Men or women, aged 18 years or greater.
  2. Subjects diagnosed with CKD-5D and in haemodialysis therapy for at least 90 days.
  3. beyond 12 months by Principal Investigator's judgement.
  4. Willingness and ability to participate after .
  5. concentrations between 9.5 g/dL and 12.5 g/dL (both values included) both at Screening Visit 1a and at Screening Visit 1b (screening Visit 1a and Visit 1b must be separated by at least 1 week).
  6. Serum ferritin \< 800 ng/mL.
  7. Transferrin Saturation \< 35%.
  8. Subjects receiving ESA treatment with dose stable for the previous 4 weeks prior to screening (with only 1 missed dose to be allowed. Dose to be kept stable during the study period).
  9. Subjects receiving no IV iron or an average of no more than 100 mg/week for the previous 4 weeks (with only 1 missed dose to be allowed).

Exclusion criteria

Exclusion Criteria:

  1. Anaemia caused primarily by factors other than renal related anaemia.
  2. Iron overload or disturbances in utilization of iron (e.g. haemochromatosis and haemosiderosis).
  3. Patients currently undergoing treatment with immunosuppresives (low dose are allowed during the study conduct for dosages no more than 10 mg prednisolone/day or equivalent. If possible the dosage should be kept constant through the study).
  4. Difference of ≥ 1.0 g/dL between screening (Visits 1a and 1b).
  5. Patients with a history of multiple allergies.
  6. Decompensated liver cirrhosis or active hepatitis [ (ALT) > 3 times normal] or history of or C.
  7. Active acute or chronic infections (assessed by clinical judgement), supplied with White Blood Cells (WBC) and C - reactive protein (CRP).
  8. Rheumatoid arthritis with symptoms or signs of active joint inflammation.
  9. Pregnancy or nursing. [To avoid pregnancy, women have to be (at least 12 months must have elapsed since last menstruation), surgically sterile, or women of child bearing potential must use one of the following during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the medicinal product: Contraceptive pills, Intrauterine Devices (IUD), contraceptive depot injections (prolonged-release gestagen), subdermal implantation, vaginal ring, and transdermal patches]
  10. Blood transfusion within the previous 12 weeks.
  11. Planned elective surgery in the next 8 weeks.
  12. Participation in any other clinical trial within the past 30 days, or if longer, where the study drug has not passed five half-lives prior to screening.
  13. Untreated Vitamin B12 or folate deficiency.
  14. Any other medical condition that, in the opinion of Principal Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study. Examples include Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
351 participants (actual)

Study arms

  • Active comparator
    Iron isomaltoside 1000

    Iron isomaltoside 1000 (Monofer)administered as 500 mg intravenous single bolus injections OR administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection

    Drug: Monofer

  • Active comparator
    Iron sucrose

    Iron sucrose administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection

    Drug: Iron sucrose

Interventions

  • Iron isomaltoside 1000 (Monofer®) administered as 500 mg intravenous single bolus injection over approximately 2 minutes

  • Iron sucrose is administered undiluted in doses of 100mg at baseline, 200mg at week 2 and 200 mg at week 4 as fractionated IV bolus injections according to local Summary of Product Characteristics

06

What researchers measure

Primary outcomes

  1. Ability to Maintain Hemoglobin Level

    The primary outcome measure was the proportion of subjects who were able to maintain haemoglobin between 9.5 and 12.5 g/dL (both values included) at week 6. Haemoglobin was measured by a blood sample at the different visits. All blood samples were taken before the dialysis from the dialysis catheter. Intravenous iron was administered during dialysis, at least 30 min after the start and at least 1 h before the end of dialysis.

    Time frame: Baseline to 6 weeks

Secondary outcomes

  1. Change in Hemoglobin Concentration

    Time frame: 6 weeks

07

Results

Posted Jul 24, 2015

Participant flow

Participant flow — Overall Study
MilestoneIron Isomaltoside 1000Iron Sucrose
Started234117
Completed210113
Not completed244

Outcome measures

PrimaryAbility to Maintain Hemoglobin Level

The primary outcome measure was the proportion of subjects who were able to maintain haemoglobin between 9.5 and 12.5 g/dL (both values included) at week 6. Haemoglobin was measured by a blood sample at the different visits. All blood samples were taken before the dialysis from the dialysis catheter. Intravenous iron was administered during dialysis, at least 30 min after the start and at least 1 h before the end of dialysis.

Time frame:
Baseline to 6 weeks
Reported as:
Number · percentage of participants
Ability to Maintain Hemoglobin Level
percentage of participantsIron Isomaltoside 1000Iron Sucrose
Ability to Maintain Hemoglobin Level82.782.6
SecondaryChange in Hemoglobin Concentration
Time frame:
6 weeks
Reported as:
Mean · g/dL
Change in Hemoglobin Concentration
g/dLIron Isomaltoside 1000Iron Sucrose
Change in Hemoglobin Concentration-0.07 (-5.5 to 2.9)-0.06 (-4.9 to 2.8)

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Iron Isomaltoside 1000—22/230 (9.6%)42/230 (18.3%)
Iron Sucrose—6/114 (5.3%)16/114 (14%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventIron Isomaltoside 1000Iron Sucrose
fallInjury, poisoning and procedural complications3/2300/114
lower respiratory tract infectionInfections and infestations1/2301/114
staphylococcol bacteraimiaInfections and infestations0/2301/114
anaesthetic complicationInjury, poisoning and procedural complications0/2301/114
road traffic accidentInjury, poisoning and procedural complications0/2301/114
prostatitisReproductive system and breast disorders0/2301/114
dyspnoeaRespiratory, thoracic and mediastinal disorders0/2301/114
arteriovenous fistula site haemorrhageInjury, poisoning and procedural complications2/2300/114
acute coronary syndromeCardiac disorders1/2300/114
acute myocardial infarctionCardiac disorders1/2300/114
Most frequent other events
Most frequent other events
EventIron Isomaltoside 1000Iron Sucrose
hyperphosphataemiaMetabolism and nutrition disorders5/2304/114
headacheNervous system disorders7/2304/114
fallInjury, poisoning and procedural complications7/2300/114
lower respiratory tract infectionInfections and infestations4/2303/114
nasopharyngitisInfections and infestations6/2301/114
C-reactive protein increasedInvestigations6/2301/114
diarrhoeaGastrointestinal disorders5/2302/114
procedural hypotensionInjury, poisoning and procedural complications5/2301/114
pain in extremityMusculoskeletal and connective tissue disorders5/2300/114

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Iron Isomaltoside 1000Iron SucroseTotal
<=18 years000
Between 18 and 65 years12966195
>=65 years10551156
Age, Continuous
Age, Continuous(years)Iron Isomaltoside 1000Iron SucroseTotal
Mean60.2 ± 16.259.5 ± 15.460.0 ± 15.9
Sex: Female, Male
Sex: Female, Male(Participants)Iron Isomaltoside 1000Iron SucroseTotal
Female7643119
Male15874232
Region of Enrollment
Region of Enrollment(participants)Iron Isomaltoside 1000Iron SucroseTotal
India442872
United Kingdom13156187
Russian Federation639
Poland10313
Sweden6410
Switzerland13619
Romania141226
Denmark6511
United States404
08

Study locations

1 site
  • Jatin Kothari
    Mumbai, India
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Oct 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2010
First posted
Oct 18, 2010
Start
Jun 2011
Primary completionActual
Oct 2013
CompletionActual
Dec 2013
Results first posted
Jul 24, 2015
Last update
Dec 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01222884
Lead sponsor
Pharmacosmos A/S
Responsible party
Sponsor
First posted
Oct 18, 2010
Start date
Jun 2011
Primary completion
Oct 2013
Completion
Dec 2013
Results posted
Jul 24, 2015
Last update
Dec 2, 2015

Study contacts

Lars Lykke Thomsen, MD
study chair · Pharmacosmos A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Iron isomaltoside 1000 · Iron sucrose

Start the discussion